https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46177 10% weight loss at three months post-treatment than HPV-negative participants (OR = 49.68, 95% CI (2.7, 912.86) p ≤ 0.01). Conclusions: The nutritional status of HPV positive and negative patients were both negatively affected by treatment and require similarly intense nutritional intervention. In acute recovery, HPV positive patients may require more intense intervention. At 3- months post treatment, both groups still showed nutritional symptoms that require nutritional intervention so ongoing nutritional support is essential.]]> Wed 28 Feb 2024 14:53:13 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25542 Wed 11 Apr 2018 11:47:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30797 Wed 11 Apr 2018 10:36:06 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37267 Tue 15 Sep 2020 13:12:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45346 Thu 27 Oct 2022 10:29:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42709 Thu 01 Sep 2022 10:02:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25915 Sat 24 Mar 2018 07:27:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51782 10 pack-years and/or distant metastases), including all patients with available tumor samples. The primary endpoint was failure-free survival (FFS) in patients receiving CETUX/RT comparing CD103+ ITIC high (≥30%) versus low (<30%). High and low CD103 were compared using Cox regression adjusting for age, stage and trial. Results: Tumor samples were available in 159/182 patients on TROG 12.01 and 145/334 on De-ESCALaTE. CD103+ ITIC abundance was high in 27% of patients. The median follow-up was 3.2 years. The 3-year FFS in patients treated with CETUX/RT was 93% [95% confidence interval (CI) 79% to 98%] in high CD103 and 74% (95% CI 63% to 81%) in low CD103 [adjusted hazard ratio = 0.22 (95% CI 0.12-0.41), P < 0.001]. The 3-year overall survival in patients treated with CETUX/RT was 100% in high CD103 and 86% (95% CI 76% to 92%) in low CD103, P < 0.001. In patients treated with CIS/RT, there was no significant difference in FFS. Conclusions: CD103+ ITIC expression separates CETUX/RT-treated low-risk HPV-associated OPSCC into excellent and poor prognosis subgroups. The high CD103 population is a rational target for de-intensification trials.]]> Mon 18 Sep 2023 15:12:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32698 Fri 03 Dec 2021 10:35:45 AEDT ]]>